معرفی
Dr. David Morse is a Professor specializing in targeted radiopharmaceutical therapies and molecular imaging. His research focuses on developing cell-surface targeted conjugates for cancer therapy and imaging, with recent emphasis on alpha-particle therapies and companion imaging tracers. He is affiliated with the Molecular Medicine Program and Metabolism and Physiology departments, collaborating with centers like the Melanoma & Skin Cancer Center of Excellence and Lung Cancer Center of Excellence. His work aims to translate novel radiopharmaceuticals for clinical use, particularly in rare melanomas, colorectal cancer, and breast cancer.
- Education: PhD in Molecular & Cellular Biology and Cancer Biology from the University of Arizona.
Research Interests: Dr. Morse’s projects include developing targeted alpha-particle therapies (TAT-RPTs) for rare melanomas, creating companion imaging tracers for radiation dosimetry, and bispecific nanobody imaging agents for surgical guidance. His studies also address the radiobiology of targeted therapies and tumor microenvironment interactions. His work bridges oncology, molecular biology, and imaging technologies to enhance therapeutic efficacy and precision.
Key Article Trends: Recent publications focus on alpha-particle therapies, fluorescence-guided surgery, and radiopharmaceutical quality control. Research spans preclinical evaluations of therapies, pharmacokinetic analyses, and tumor-targeting ligand development, emphasizing translational applications.
Grants: Current funding includes projects on MUC16-targeted therapies, orexin receptor agonist discovery, and translational studies for melanoma therapies, supported by the Department of Defense and private foundations.
Labs/Teams: Collaborates with interdisciplinary teams at Moffitt Cancer Center, focusing on experimental therapeutics and cancer imaging technologies.
